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Abstract
Background: Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of non-Hodgkin diffuse large B-cell
lymphoma originally with a predilection to the oral cavity of patients infected with HIV. However, PBL of extraoral
sites possesses clinicopathological characteristics distinct from oral PBL. Recently, therapeutic approaches using a
proteasome inhibitor bortezomib to PBL of extraoral sites have been reported. We present a PBL patient with a
bulky tumor of the oral cavity, who dramatically responded to bortezomib.
Case Presentation: The patient was a 58 year-old Japanese male, who presented with a rapidly progressive history
of a swelling on his left cheek and restricted mouth opening. He did not have a history or evidence of
immunosuppression including HIV infection. A computed tomography demonstrated a bulky tumor in the oral
cavity without enlarged lymph nodes. The tumor showed the proliferation of large lymphoid cells with
centroblastic morphology, which were positive for CD138, CD38, CD56 and MUM-1, and negative for CD20, CD79a,
BCL-6 and HHV8. The Ki-67 proliferation index was almost 100 %. Neither osteolytic lesions nor M-protein was
observed. One week after the initiation of bortezomib, a marked regression of the oral tumor was obtained.
Conclusions: Thus, our case demonstrated the effectiveness of bortezomib on PBL of the oral cavity as well as the
extraoral sites.
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Background
Plasmablastic lymphoma (PBL) was originally described in
1997 by Delecluse et al., as an aggressive variant of large
B-cell lymphoma with plasmablastic features occurs in the
oral cavity or in the jaw of human immunodeficiency virus
(HIV)-infected patients [1]. PBL has been initially seen in
the clinical setting of HIV infection. The tumor cells are
large lymphoid cells with centroblastic/immunoblastic fea-
tures, which typically express plasma cell markers such as
CD38 and CD138, and lack expression of mature B-cell
markers. This lymphoma exhibits rapid disease progres-
sion and resistance to various chemotherapy regimens [2].
However, the development of PBL in HIV-negative
patients has been recently reported [3]. When compared
with HIV-positive PBL, HIV-negative PBL tends to occur
in extraoral sites and morphologically shows a more ap-
parent plasma cell differentiation [4–6].
Because of the rarity and aggressiveness of the disease,
no standard chemotherapy for PBL has been established.
In this regard, therapeutic approach with bortezomib to
HIV-negative PBL [7–9] and HIV-positive PBL [9–11] has
been recently reported. However, primary sites of involve-
ment in these PBL patients treated with bortezomib were
extraoral. We herein report a case with PBL of the oral
cavity morphologically showing centroblastic features as
reported by Delecluse et al. [1]. Bortezomib induced a
dramatic regression of a bulky tumor in the oral cavity of
the patient.
Case presentation
The patient is a 58 year-old Japanese male presented
with a rapidly progressive history of a swelling on his
left cheek and restricted mouth opening. He had no his-
tory of HIV infection, multiple myeloma or underlying
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immunosuppression. Physical examination showed a
bleeding tumor of the oral cavity. The laboratory find-
ings on admission were: hemoglobin 10.9 g/dL, white
blood cell count 11.4×109/L, platelet 197×109/L serum
lactate dehydrogenase (LDH) 2232 U/L (normal value:
119–229), serum creatinine 1.68 mg/dL (normal value:
0.6–1.1), serum uric acid 12.7 mg/dL (normal value:
3.6–8.0), serum potassium 4.9 mg/dL (normal value:
3.6–4.9), serum phosphorus 6.2 mg/dL (normal value:
2.5–4.7), serum calcium 11.3 mg/dL (normal value:
8.7–10.3). Serum IgG, IgM, and IgA levels were within
the normal range. Serum protein electrophoresis had no
M-spike. Serology for HIV was negative. There were no
osteolytic lesions on bone survey. A computed tomog-
raphy (CT) demonstrated a bulky tumor localized in the
mucosa of the oral cavity (Fig. 1a), without enlargement of
the systemic lymph nodes. Biopsy of the oral mass showed
diffuse proliferation of large lymphoid cells (Fig. 2a) with
centroblastic morphology, which were positive for CD138
(Fig. 2b), CD38 (Fig. 2c), CD56, and MUM-1 (Fig. 2d)
and negative for CD20 (Fig. 2e), CD79a (Fig. 2f ), CD3
and BCL-6. EBV-encoded RNA in situ hybridization
(EBER-ISH) (Fig. 2g) and HHV8 (Fig. 2h) were nega-
tive. The Ki-67 proliferation index was almost 100 %
(Fig. 2i). No apparent plasmacytic differentiation of
the tumor cells was observed. G-banding analysis of
the tumor showed abnormal karyotypes: 46, X, −Y,
dup(1)(q42q21), −6, +7, +7, −8, add(14)(q32),
add(20)(p11.2), +mar/ 82<3n>, XX,-Y, dup(1)×2, −4,
+5, +6, +6, +7, +7, +7, +7, +7, −8, −8, +9, +9, +11,
add(14)×2, +15, +5mar. Although no lymphoma cells
were found in his peripheral blood, bone marrow examin-
ation showed infiltration of large atypical lymphoid cells,
suggesting bone marrow involvement. The patient was di-
agnosed with stage IVA PBL.
Immediately after diagnosis, the patient was treated with
THP-COP composed of pirarubicin, cyclophosphamide,
vincristine and prednisolone. Since pirarubicin (THP) has
been reported to have comparable efficacy to doxorubicin
with a lower incidence of cardiac toxicity in aggressive
non-Hodgkin lymphoma treatment, THP-COP therapy
was used [12]. Intravenous hydration and allopurinol also
started.
Despite the prompt treatment, the oral tumor contin-
ued to enlarge, with increasing risk of suffocation.
Therefore, bortezomib was started on day 9 of admis-
sion. Bortezomib was given at a dose of 1.3 mg/m2 on
days 1, 8 and 15 without dexamethasone in the first
cycle. In the second cycle, the patient was treated with
bortezomib in combination with dexamethasone. One
week after the initiation of bortezomib, a marked regres-
sion of the oral tumor was observed, and one month
after its initiation, no significant swelling of the oral cavity
was detected (Fig. 1b). Serum LDH levels also rapidly
improved. However, since resistance to bortezomib devel-
oped after the third cycle of bortezomib, the patient was
salvaged with EPOCH and irradiation. He had disease-
progression and died five months post-diagnosis.
Discussion
The original report by Delecluse et al. described a series
of 16 patients with PBL [1]. They all presented with the
involvement of the oral cavity. 15 of the 16 PBL patients
were infected with HIV. Resistance of PBL to various
chemotherapy regimens even in the multidrug setting or
combined with radiotherapy has been shown. The treat-
ment outcome for PBL generally remains poor with a
short survival [2].
The occurrence of PBL in HIV-negative individuals
has been also recognized [3]. Although HIV-negative
Fig. 1 Transverse CT scan of the oral cavity showing an oral tumor at diagnosis (a) and 30 days after the initiation of bortezomib treatment (b)
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PBL has been initially thought to be associated with
an underlying immunosuppressive state including
organ transplantation, autoimmune diseases and lym-
phoproliferative diseases, no significant immunodefi-
ciency was found in other cases [3, 6]. In addition,
comparative studies between HIV-positive and HIV-
negative PBL have been reported [4–6]. When compared
with HIV-negative PBL, PBL of the oral cavity tends to
occur in HIV-positive patients and shows morphological
features of centroblasts or immunoblasts without plasmacy-
tic differentiation, as originally described by Delecluse et al.
[1]. On the other hand, extraoral PBL appears to occur in
HIV-negative patients morphologically with a more appar-
ent plasma cell differentiation. Thus, clinicopathological dif-
ferences between oral PBL and extraoral PBL have been
pointed out.
Several studies have reported PBL cases treated with a
proteosome inhibitor bortezomib [7–11]. Bose et al.
showed a HIV-positive patient with PBL of the extraoral
sites, who had dramatic disease regression following
only two doses of bortezomib (days 1 and 4) [10]. A
rapid improvement of HIV-negative PBL tumor infil-
trating the left gluteus and erector spinae muscles
after the first cycle of BD therapy (bortezomib plus
dexamethasone) was also reported [7]. Tumor lysis syn-
drome was induced by bortezomib combined with ritux-
imab, cyclophosphamide and dexamethasone (R-
CBortP) in a patient with HIV-negative PBL of the
extraoral sites, 24–48 h after the first injection of
bortezomib [8]. Moreover, early disease relapses have
been observed despite the initial response to bortezo-
mib. In this regard, a study using three PBL patients (two
HIV-positive and one HIV-negative) demonstrated a dur-
able response of PBL to a combination of bortezomib
with dose-adjusted EPOCH with the disease-free survival
ranged from 12 to 24 months [9]. However, in these
Fig. 2 a Hematoxylin and eosin staining showing large lymphoid cells with centroblastic morphology (X400). Cells of the oral tumor (X200) were
immunohistologically positive for b CD138 and c CD38, d MUM-1, and were negative for e CD20, f CD79a, g EBV-encoded RNA in situ hybridization
(EBER-ISH) and h HHV8. i The Ki-67 proliferation index was almost 100 %
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previous reports using bortezomib, the primary sites of
PBL involvement were extraoral.
Carbone et al. reported that HIV-associated PBL con-
sistently shows the BCL-6 negative/IRF4 (MUM-1) posi-
tive/CD138 (Syn-1) positive phenotype, and therefore
reflects post-germinal center (GC) B-cells in all cases ex-
amined [13]. They pointed out that post-GC cells under-
going maturation toward plasma cells switch off BCL-6
expression. In this regard, the original report by Delecluse
et al. showed that only a weak and partial expression of
BCL-6 was detected in 4 of 14 tested cases, whereas the
remaining cases were negative for BCL-6 [1]. Activated B-
cell-like (ABC) diffuse large B-cell lymphoma (DLBCL),
arises from post-GC B-cell, is characterized by constitutive
activation of the NF-KB pathway. Bortezomib has been
demonstrated to enhance the activity of chemotherapy in
ABC DLBCL, but not in GC DLBCL [14]. These findings
show a potential benefit of bortezomib in treatment for
PBL as well as for ABC DLBCL. However, they further
pointed out that bortezomib was inactive as a single agent,
suggesting that tumor growth is regulated by additional
anti-apoptotic signals unaffected by bortezomib [14].
Thus, getting a better understanding of the unique
features of PBL is essential. Our report demonstrates
therapeutic benefit of bortezomib for PBL of the oral
cavity as well as extraoral PBL.
Conclusion
PBL is an aggressive variant of large B-cell lymphoma, ori-
ginally with a predilection to the oral cavity of patients in-
fected with HIV. Herein, our report presents with the first
case of PBL of the oral cavity, who showed a drastic re-
sponse to bortezomib. Symptoms of the patient immedi-
ately disappeared following bortezomib administration.
The tumor regression was further obtained without cyto-
toxic chemotherapy.
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